Patent · US Active

PD-L1 antibodies and uses thereof

US9885721B2 · kind B2 · utility

5Cited by

9References

12Claims

0Family size

Assignee

Spring BioScience Corporation · US

Inventors

Fernando Jose Rebelo do Couto · Pleasanton, US
Zhiming Liao · Livermore, US
Yifei Zhu · Alpharetta, US

Key dates

Filing date	May 29, 2015
Grant date	Feb 6, 2018
Priority date	—
Expiry date	May 29, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70596
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Provided herein are PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.